Greg Harrison
Stock Analyst at B of A Securities
(4.62)
# 210
Out of 5,139 analysts
104
Total ratings
59.49%
Success rate
26.61%
Average return
Main Sectors:
Stocks Rated by Greg Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGIO Agios Pharmaceuticals | Maintains: Buy | $32 → $34 | $27.19 | +25.05% | 9 | Dec 24, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $36 → $30 | $12.50 | +140.00% | 3 | Oct 27, 2025 | |
| UTHR United Therapeutics | Maintains: Neutral | $314 → $463 | $464.93 | -0.42% | 5 | Sep 2, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $38 → $43 | $32.74 | +31.34% | 2 | Aug 28, 2025 | |
| TVTX Travere Therapeutics | Maintains: Sector Outperform | $30 → $31 | $27.87 | +11.23% | 6 | Aug 7, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Sector Outperform | $22 → $20 | $11.27 | +77.46% | 2 | Aug 6, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Sector Outperform | $55 → $57 | $76.26 | -25.26% | 7 | Aug 6, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $442 → $438 | $441.36 | -0.76% | 7 | Aug 5, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Sector Outperform | $342 → $450 | $359.27 | +25.25% | 6 | Aug 1, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Neutral | $9 → $4 | $3.64 | +9.89% | 8 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $11 | $2.52 | +336.51% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $32 → $35 | $7.29 | +380.11% | 2 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $65 → $55 | $46.51 | +18.25% | 3 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $36 → $37 | $37.93 | -2.45% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $41 → $26 | $18.86 | +37.86% | 6 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $28 → $20 | $19.94 | +0.30% | 4 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $4 → $1.5 | $1.31 | +14.50% | 3 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $40 | $31.22 | +28.12% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $73 → $75 | $70.93 | +5.74% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $18 | $15.08 | +19.36% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $28.70 | -58.19% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $5 → $1.5 | $0.40 | +273.69% | 1 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $15 | $2.03 | +638.92% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 | $12.01 | -75.02% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $1.03 | +6,696.12% | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $54 | $13.90 | +288.49% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $270 → $90 | $37.68 | +138.85% | 5 | Mar 14, 2022 |
Agios Pharmaceuticals
Dec 24, 2025
Maintains: Buy
Price Target: $32 → $34
Current: $27.19
Upside: +25.05%
Intellia Therapeutics
Oct 27, 2025
Maintains: Buy
Price Target: $36 → $30
Current: $12.50
Upside: +140.00%
United Therapeutics
Sep 2, 2025
Maintains: Neutral
Price Target: $314 → $463
Current: $464.93
Upside: -0.42%
Mineralys Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $38 → $43
Current: $32.74
Upside: +31.34%
Travere Therapeutics
Aug 7, 2025
Maintains: Sector Outperform
Price Target: $30 → $31
Current: $27.87
Upside: +11.23%
Ocular Therapeutix
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $22 → $20
Current: $11.27
Upside: +77.46%
BridgeBio Pharma
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $55 → $57
Current: $76.26
Upside: -25.26%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Sector Perform
Price Target: $442 → $438
Current: $441.36
Upside: -0.76%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Sector Outperform
Price Target: $342 → $450
Current: $359.27
Upside: +25.25%
Rocket Pharmaceuticals
Jul 25, 2025
Downgrades: Neutral
Price Target: $9 → $4
Current: $3.64
Upside: +9.89%
Jul 14, 2025
Initiates: Sector Outperform
Price Target: $11
Current: $2.52
Upside: +336.51%
Jul 2, 2025
Maintains: Sector Outperform
Price Target: $32 → $35
Current: $7.29
Upside: +380.11%
Jun 2, 2025
Maintains: Sector Outperform
Price Target: $65 → $55
Current: $46.51
Upside: +18.25%
May 28, 2025
Maintains: Sector Outperform
Price Target: $36 → $37
Current: $37.93
Upside: -2.45%
May 12, 2025
Maintains: Sector Outperform
Price Target: $41 → $26
Current: $18.86
Upside: +37.86%
May 8, 2025
Maintains: Sector Perform
Price Target: $28 → $20
Current: $19.94
Upside: +0.30%
May 8, 2025
Downgrades: Sector Perform
Price Target: $4 → $1.5
Current: $1.31
Upside: +14.50%
Mar 10, 2025
Upgrades: Sector Outperform
Price Target: $40
Current: $31.22
Upside: +28.12%
Mar 3, 2025
Maintains: Sector Outperform
Price Target: $73 → $75
Current: $70.93
Upside: +5.74%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $18
Current: $15.08
Upside: +19.36%
May 1, 2023
Upgrades: Neutral
Price Target: $9 → $12
Current: $28.70
Upside: -58.19%
Apr 28, 2023
Downgrades: Underperform
Price Target: $5 → $1.5
Current: $0.40
Upside: +273.69%
Nov 18, 2022
Maintains: Neutral
Price Target: $18 → $15
Current: $2.03
Upside: +638.92%
Nov 8, 2022
Downgrades: Underperform
Price Target: $3
Current: $12.01
Upside: -75.02%
Sep 29, 2022
Initiates: Buy
Price Target: $70
Current: $1.03
Upside: +6,696.12%
Mar 16, 2022
Maintains: Buy
Price Target: $67 → $54
Current: $13.90
Upside: +288.49%
Mar 14, 2022
Downgrades: Underperform
Price Target: $270 → $90
Current: $37.68
Upside: +138.85%